6:12 PM
 | 
Dec 10, 2012
 |  BC Extra  |  Clinical News

BMS, Pfizer report data for extended Eliquis treatment

Bristol-Myers Squibb Co. (NYSE:BMY) and partner Pfizer Inc. (NYSE:PFE) said twice-daily 2.5 and 5 mg Eliquis apixaban for one year as extended treatment for venous thromboembolism (VTE) each met the composite primary endpoint in the Phase III AMPLIFY-EXT trial. The endpoint...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >